U.S. flag

An official website of the United States government

NM_000535.7(PMS2):c.2249G>A (p.Gly750Asp) AND Hereditary cancer-predisposing syndrome

Germline classification:
Pathogenic/Likely pathogenic (3 submissions)
Last evaluated:
Jan 3, 2024
Review status:
2 stars out of maximum of 4 stars
criteria provided, multiple submitters, no conflicts
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000115679.15

Allele description [Variation Report for NM_000535.7(PMS2):c.2249G>A (p.Gly750Asp)]

NM_000535.7(PMS2):c.2249G>A (p.Gly750Asp)

Gene:
PMS2:PMS1 homolog 2, mismatch repair system component [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
7p22.1
Genomic location:
Preferred name:
NM_000535.7(PMS2):c.2249G>A (p.Gly750Asp)
HGVS:
  • NC_000007.14:g.5978622C>T
  • NG_008466.1:g.35485G>A
  • NM_000535.7:c.2249G>AMANE SELECT
  • NM_001322003.2:c.1844G>A
  • NM_001322004.2:c.1844G>A
  • NM_001322005.2:c.1844G>A
  • NM_001322006.2:c.2093G>A
  • NM_001322007.2:c.1931G>A
  • NM_001322008.2:c.1931G>A
  • NM_001322009.2:c.1844G>A
  • NM_001322010.2:c.1688G>A
  • NM_001322011.2:c.1316G>A
  • NM_001322012.2:c.1316G>A
  • NM_001322013.2:c.1676G>A
  • NM_001322014.2:c.2249G>A
  • NM_001322015.2:c.1940G>A
  • NP_000526.2:p.Gly750Asp
  • NP_001308932.1:p.Gly615Asp
  • NP_001308933.1:p.Gly615Asp
  • NP_001308934.1:p.Gly615Asp
  • NP_001308935.1:p.Gly698Asp
  • NP_001308936.1:p.Gly644Asp
  • NP_001308937.1:p.Gly644Asp
  • NP_001308938.1:p.Gly615Asp
  • NP_001308939.1:p.Gly563Asp
  • NP_001308940.1:p.Gly439Asp
  • NP_001308941.1:p.Gly439Asp
  • NP_001308942.1:p.Gly559Asp
  • NP_001308943.1:p.Gly750Asp
  • NP_001308944.1:p.Gly647Asp
  • LRG_161t1:c.2249G>A
  • LRG_161:g.35485G>A
  • NC_000007.13:g.6018253C>T
  • NM_000535.5:c.2249G>A
  • NM_000535.6:c.2249G>A
  • NR_136154.1:n.2336G>A
  • p.G750D
Protein change:
G439D
Links:
dbSNP: rs587779337
NCBI 1000 Genomes Browser:
rs587779337
Molecular consequence:
  • NM_000535.7:c.2249G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001322003.2:c.1844G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001322004.2:c.1844G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001322005.2:c.1844G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001322006.2:c.2093G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001322007.2:c.1931G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001322008.2:c.1931G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001322009.2:c.1844G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001322010.2:c.1688G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001322011.2:c.1316G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001322012.2:c.1316G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001322013.2:c.1676G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001322014.2:c.2249G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001322015.2:c.1940G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NR_136154.1:n.2336G>A - non-coding transcript variant - [Sequence Ontology: SO:0001619]

Condition(s)

Name:
Hereditary cancer-predisposing syndrome
Synonyms:
Neoplastic Syndromes, Hereditary; Tumor predisposition; Cancer predisposition; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0015356; MeSH: D009386; MedGen: C0027672

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000172925Ambry Genetics
criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)
Pathogenic
(Jul 23, 2021)
germlineclinical testing

PubMed (4)
[See all records that cite these PMIDs]

Citation Link,

SCV002530277Sema4, Sema4
criteria provided, single submitter

(Sema4 Curation Guidelines)
Likely pathogenic
(Mar 15, 2022)
germlinecuration

PubMed (9)
[See all records that cite these PMIDs]

Citation Link,

SCV004359029Color Diagnostics, LLC DBA Color Health
criteria provided, single submitter

(ACMG Guidelines, 2015)
Likely pathogenic
(Jan 3, 2024)
germlineclinical testing

PubMed (8)
[See all records that cite these PMIDs]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing, curation

Citations

PubMed

Structure of the MutLα C-terminal domain reveals how Mlh1 contributes to Pms1 endonuclease site.

Gueneau E, Dherin C, Legrand P, Tellier-Lebegue C, Gilquin B, Bonnesoeur P, Londino F, Quemener C, Le Du MH, Márquez JA, Moutiez M, Gondry M, Boiteux S, Charbonnier JB.

Nat Struct Mol Biol. 2013 Apr;20(4):461-8. doi: 10.1038/nsmb.2511. Epub 2013 Feb 24.

PubMed [citation]
PMID:
23435383

Full-length transcript amplification and sequencing as universal method to test mRNA integrity and biallelic expression in mismatch repair genes.

Morak M, Schaefer K, Steinke-Lange V, Koehler U, Keinath S, Massdorf T, Mauracher B, Rahner N, Bailey J, Kling C, Haeusser T, Laner A, Holinski-Feder E.

Eur J Hum Genet. 2019 Dec;27(12):1808-1820. doi: 10.1038/s41431-019-0472-8. Epub 2019 Jul 22.

PubMed [citation]
PMID:
31332305
PMCID:
PMC6870986
See all PubMed Citations (11)

Details of each submission

From Ambry Genetics, SCV000172925.8

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (4)

Description

The p.G750D pathogenic mutation (also known as c.2249G>A), located in exon 13 of the PMS2 gene, results from a G to A substitution at nucleotide position 2249. The glycine at codon 750 is replaced by aspartate, an amino acid with similar properties. In one study, this alteration was detected in trans with a full gene PMS2 deletion and the severe phenotype in this family was consistent with biallelic PMS2 mutations. The proband was diagnosed with rectal cancer at age 22 and a brain tumor at age 23, while a brother was diagnosed with colorectal cancer (CRC) at age 21. The proband's tumor as well as adjacent normal tissue demonstrated loss of PMS2 expression on IHC (Senter et al. Gastroenterology. 2008 August; 135(2): 419–428). In another family, the p.G750D alteration was reported in conjunction with the PMS2 frameshift mutation c.2019delT in a proband with café-au-lait macules, a glioblastoma at age 31, and CRC at age 32. Tumor testing showed MSI-H and absence of PMS2 staining on IHC. This patient's family history included hematologic cancers, renal cancer, and CRC (van Galen et al. Hereditary Cancer in Clinical Practice. 2011, 9(Suppl 1):P38). This alteration was also reported in a suspected Lynch syndrome family and the proband had co-occurrence with PMS2 p.E330_E381del. The clinical features of the proband included: CRC diagnosed twice at ages 22 and 32, polyps at age 38, a glioblastoma at age 40, and café-au-lait macules (Lavoine N et al. J. Med. Genet. 2015 Nov;52:770-8). In another study, this alteration was reported in conjunction with PMS2 p.S46I in a male with colon cancer diagnosed at ages 41 and 50 and tumor results demonstrated MSI-H as well as loss of PMS2 expression on IHC (Goodenberger ML et al. Genet. Med. 2016 Jan;18:13-9). Based on an internal structural analysis, this variant is anticipated to result in a significant decrease in protein structural stability (Gueneau E et al. Nat. Struct. Mol. Biol. 2013 Apr; 20(4):461-8). This missense alteration is located in a region that has a low rate of benign missense variation (Lek M et al. Nature. 2016 Aug 18;536(7616):285-91; DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans using Ensembl Resources. Firth H.V. et al. 2009. Am.J.Hum.Genet. 84, 524-533 (DOI: dx.doi.org/10/1016/j.ajhg.2009.03.010)). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From Sema4, Sema4, SCV002530277.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedcuration PubMed (9)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From Color Diagnostics, LLC DBA Color Health, SCV004359029.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (8)

Description

This missense variant replaces glycine with aspartic acid at codon 750 in the nuclease domain of the PMS2 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Functional studies have shown that this variant protein partially reduces DNA mismatch repair activity compared with wild type protein in in vitro-based assays (PMID: 24027009, 26116798, 30608896). This variant has been reported in heterozygous state with a second pathogenic PMS2 variant (PMID: 18602922, 26116798, 26318770; DOI: 10.1186/1897-4287-9-S1-P38), or in heterozygous state with an unknown second pathogenic variant (PMID: 30608896), in individuals affected with constitutional mismatch repair deficiency (CMMRD). Of note, these individuals had cancer onset age later than typical individuals with CMMRD. This variant has been reported in individuals affected with colorectal cancer exhibiting clinical features of Lynch syndrome (PMID: 25856668, co-occurring with the pathogenic Ser46Ile PMS2 variant), or ovarian cancer (PMID: 34371384). This variant has been identified in 1/249726 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Likely Pathogenic. The partial functional impact and later cancer onset age suggest that this variant may not be associated with the same cancer risk as a typical PMS2 pathogenic variant.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Nov 24, 2024